8-K: Inovio Pharmaceuticals Announces Second Quarter 2024 Financial Results and Provides Business Update

Inovio Pharmaceuticals reported its second quarter 2024 financial results, highlighted by a delay in the BLA submission for INO-3107 due to a manufacturing issue, but also progress in other clinical programs and a strengthened balance sheet.

Summary

• Inovio Pharmaceuticals announced its financial results for the second quarter of 2024, reporting a net loss of $32.2 million, or $1.19 per share.
• The company's cash, cash equivalents, and short-term investments totaled $110.4 million as of June 30, 2024, compared to $145.3 million at the end of 2023.
• Research and development expenses were $23.1 million for the quarter, slightly down from $23.7 million in the same period last year.
• General and administrative expenses decreased to $10.2 million from $13.5 million year-over-year.
• Total operating expenses were $33.3 million for the quarter, compared to $37.3 million in the second quarter of 2023.
• The company expects its cash runway to extend into the third quarter of 2025, with an estimated operational net cash burn of approximately $28 million for the third quarter of 2024.
• A manufacturing issue with a component of the CELLECTRA device has delayed the BLA submission for INO-3107 to mid-2025.
• Inovio has made progress with other programs, including submitting Phase 3 clinical plans for INO-3112 to European regulatory authorities and planning to resubmit Phase 2 clinical plans for INO-4201 to the FDA.
• The company also appointed Steve Egge as Chief Commercial Officer.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the delay in the BLA submission, which is a significant setback. However, the company has made progress in other areas and has a cash runway into Q3 2025, which provides some stability.

Positives

• Inovio strengthened its balance sheet with a $33.2 million capital raise.
• INO-3107 received an Innovation Passport in the U.K. and an ATMP Certification from the European Medicines Agency.
• The company has made progress with other programs, including submitting Phase 3 clinical plans for INO-3112 to European regulatory authorities.
• INO-4201's Phase 2 clinical plans are expected to be resubmitted to the FDA in the third quarter.
• Steve Egge, a highly experienced commercial leader, was appointed as Chief Commercial Officer.
• The company's cash runway is projected to extend into the third quarter of 2025.

Negatives

• The BLA submission for INO-3107 has been delayed to mid-2025 due to a manufacturing issue with the device's disposable component.
• Inovio reported a net loss of $32.2 million for the second quarter of 2024.
• Cash reserves decreased from $145.3 million at the end of 2023 to $110.4 million as of June 30, 2024.

Risks

• The manufacturing issue with the CELLECTRA device component could lead to further delays in the BLA submission for INO-3107.
• The company's cash burn rate could impact its ability to fund ongoing research and development.
• There is no guarantee that any product candidate will be successfully developed, manufactured, or commercialized.
• Clinical trial results may not support regulatory approvals.
• The company faces competition from other therapies and treatments.
• The company's patents may not provide meaningful protection from others using the covered technologies.

Future Outlook

Inovio expects to submit the BLA for INO-3107 in mid-2025 and anticipates its cash runway to extend into the third quarter of 2025. The company also plans to advance other clinical programs and commercial preparations.

Management Comments

• Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer, stated that they continue to make progress with INO-3107 and are taking corrective steps to address the manufacturing issue.
• Dr. Shea also mentioned that they have not altered their ultimate expectations for INO-3107 to be a potentially transformative therapeutic option for RRP patients.
• Dr. Shea noted that they have continued making progress in other key areas of their business.

Industry Context

This announcement comes as the biotechnology industry continues to face challenges in drug development and regulatory approvals. The delay in the BLA submission for INO-3107 highlights the complexities of manufacturing and regulatory processes. However, the progress in other clinical programs and the appointment of a new Chief Commercial Officer indicate Inovio's commitment to advancing its pipeline.

Comparison to Industry Standards

• The delay in BLA submission due to manufacturing issues is not uncommon in the pharmaceutical industry, with companies like Sanofi and Pfizer having experienced similar setbacks in the past.
• Inovio's cash burn rate is comparable to other clinical-stage biotech companies, such as Moderna and BioNTech, which also invest heavily in R&D.
• The company's focus on DNA medicines is a unique approach compared to traditional vaccine and therapeutic development, which is more common in companies like GSK and Merck.
• The ATMP certification from the European Medicines Agency is a positive sign, similar to approvals received by other companies developing advanced therapies, such as bluebird bio and Novartis.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the delay in the BLA submission for INO-3107 and the decrease in cash reserves.
• Employees may be affected by the company's financial performance and the need to address the manufacturing issue.
• Patients with RRP may have to wait longer for a potential treatment option.
• Partners and collaborators may be impacted by the delay in the BLA submission and the company's financial situation.

Next Steps

• Inovio will work to rectify the manufacturing issue with the CELLECTRA device component.
• The company will continue to advance all other elements necessary for INO-3107's success, including initiating the confirmatory trial and advancing plans for the redosing trial.
• Inovio will continue to make key regulatory progress in Europe and the U.K.
• The company will continue commercial preparations to be launch-ready if they receive approval for INO-3107.
• Inovio anticipates resubmitting its Phase 2 clinical plans for INO-4201 to the FDA in the third quarter.
• The company will continue discussions with partners to advance INO-5401 as a potential treatment for GBM.

Key Dates

Keywords

INO-3107, INO-3112, INO-4201, DNA medicines, CELLECTRA, BLA, RRP, HPV, Ebola, Biotechnology, Clinical Trials, Regulatory Approval, Manufacturing, Financial Results